Motif Bio PLC Appointment of Chief Financial Officer (4121U)
18 Gennaio 2017 - 8:00AM
UK Regulatory
TIDMMTFB
RNS Number : 4121U
Motif Bio PLC
18 January 2017
18 January 2017
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION
This announcement contains inside information.
Motif Bio plc
("Motif Bio" or the "Company")
Appointment of Chief Financial Officer
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that Robert Dickey IV has been appointed as Chief Financial
Officer.
Mr. Dickey is an accomplished financial professional with senior
leadership experience in private and public healthcare companies.
Prior to joining Motif Bio, he was CFO at Tyme Technologies Inc., a
NASDAQ-listed clinical stage oncology company. Robert previously
held senior leadership positions at NeoStem, Inc. (now known as
Caladrius Biosciences Inc.), Hemispherx Biopharma Inc., Stemcyte
Inc., Locus Pharmaceuticals Inc. and Protarga Inc. Mr. Dickey began
his career as an Investment Banker at Lehman Brothers and Legg
Mason Wood Walker Inc.
Pete Meyers is leaving Motif Bio and has agreed to transition
the CFO responsibilities to Mr. Dickey over the course of the next
several weeks.
Graham Lumsden, CEO commented: "I am delighted that Rob has
agreed to join Motif Bio at this important time as we await data
read-out in the second quarter of 2017 from REVIVE-1, our Phase 3
clinical trial in patients with ABSSSI (Acute Bacterial Skin and
Skin Structure Infections). Rob's proven leadership and strategic
skills will be a tremendous addition to the team. I am immensely
grateful to Pete Meyers for his tireless dedication and hard work
during 2016, culminating in a successful NASDAQ IPO and raise of
$25 million. I wish him well in his future endeavours."
For further information please contact:
Motif Bio plc info@motifbio.com
Richard Morgan (Chairman)
Graham Lumsden (Chief
Executive Officer)
Zeus Capital Limited
(NOMAD & BROKER)
Phil Walker/Giles Balleny
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners
Limited (BROKER)
Patrick Claridge/ David
Hignell
John Howes/ Rob Rees
(Broking) +44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or
PR & IR) motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio plc www.motifbio.com
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), which
is often caused by MRSA (methicillin resistant Staphylococcus
aureus). We are currently enrolling and dosing patients in two
global Phase 3 clinical trials (Revive 1 and Revive 2) with an
intravenous formulation of iclaprim, for the treatment of ABSSSI.
Data readout for REVIVE-1 is expected in the second quarter of 2017
and REVIVE-2 is on track for data readout in the second half of
2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUBAARBUAAAUR
(END) Dow Jones Newswires
January 18, 2017 02:00 ET (07:00 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024